JH:
I have previously explained my view that a lot of senescent cells are stem cells that have got stuck in the process of becoming somatic cells (the daughter cells that are somatic) and often act as adipocytes. This was criticised and I gave the papers that justified this. It is a good debate to have, but if someone wants to have it please ask me first to find the topic that this was discussed on and then take the debate from those points.
chatGPT:
Summary
The paper is a 2026 review article, “The love and hate relationship between cellular senescence and stemness”, by Papaspyropoulos et al. It reviews how cellular senescence and stemness can either oppose or reinforce each other depending on tissue type, developmental state, disease setting, and especially cancer context.
The central framing is that senescence and stemness look biologically opposed: senescent cells are usually growth-arrested, whereas stem cells depend on self-renewal and proliferative capacity. However, the authors argue that this is too simple. Senescence can block regenerative stem-cell function in some settings, but in others—particularly cancer—senescent-cell features can help generate or support stem-like malignant cells.
Main argument
In normal adult tissues, senescence is generally presented as a barrier to stemness. The review discusses several examples:
Mesenchymal stem cells can become senescent during culture expansion or aging, reducing their regenerative utility. In placental MSCs, rapamycin/mTOR inhibition is discussed as a way to reduce senescence and preserve regenerative potential.
Bone marrow MSCs from elderly donors show increased p21, p16, G1 arrest, telomere damage and reduced osteogenic differentiation. The review highlights NAP1L2 as a regulator of BMSC senescence and impaired differentiation.
Adipose-derived MSCs lose stemness during long-term culture, apparently linked to ROS and oxidative stress. Antioxidants such as reduced glutathione and melatonin are described as preserving ADSC function by limiting ROS.
Muscle satellite cells are a key example: aging-associated derepression of p16INK4A pushes quiescent satellite cells toward pre-senescence and reduces regenerative capacity. Slug is presented as a p16 repressor whose loss contributes to age-related satellite-cell decline.
Dental pulp stem cells are discussed through NUP62, nuclear transport, E2F1 and NSD2, with NUP62 loss contributing to senescence and reduced differentiation. Hypoxia is also described as preserving stemness and reducing senescence markers in these cells.
Pancreatic β-cell progenitors are another example, where p16INK4A limits CDK4 activity, β-cell proliferation and islet regeneration with age.
The paper then turns to cases where senescence and stemness are synergistic, mainly in cancer. Here, senescence can create a dangerous intermediate state: cells are growth-arrested at first, but they acquire stemness traits, SASP signalling, Wnt activation, invasion capacity, and in some cases the ability to escape senescence.
Examples include:
B-cell lymphoma, where chemotherapy-induced senescent lymphoma cells acquire stem-cell signatures, Wnt activation and greater tumour-initiation potential after escaping senescence.
Relapsed/refractory B-cell non-Hodgkin lymphoma, where therapy-induced senescence is associated with CCR7-high memory-like B cells, invasion and stemness features.
Multiple myeloma, where SASP from senescent non-CSC populations can promote emergence of cancer stem cells, with CHK2 implicated in SASP-driven CSC generation.
In vivo OSKM reprogramming, where senescence and reprogramming can occur together, with IL-6 creating a permissive environment.
Skin keratinocytes, where transient SASP can enhance regenerative potential but chronic SASP suppresses proliferation.
Mammary gland and breast cancer models, where RANK/RANKL induces senescence but also promotes stemness and invasion.
Hepatocellular carcinoma, where doxorubicin-induced senescence increases stemness markers and may convert non-CSCs toward CSC-like states through EpCAM and Wnt/β-catenin signalling.
Colon cancer, where PLD2 released by cancer cells induces fibroblast senescence, whose SASP then feeds back to increase cancer-cell stemness and Wnt signalling.
Lung epithelial cancer models, where oncogene-induced senescence escape is associated with chromosomal inversion, BHLHE40 activation and acquisition of aggressive stemness-like properties.
The authors conclude that senescence targeting is clinically delicate. Senescence suppression may help preserve tissue regeneration in aging, but senescence induction can be useful as a tumour-suppressive arrest. Conversely, therapy-induced senescence in cancer may backfire if senescent cells persist, acquire SASP, promote CSCs, or escape into more aggressive states.
Novelty
The article’s novelty is not that it reports new experiments—it is a review, not a primary research paper. Its contribution is conceptual and integrative.
The useful novelty is the two-axis framing: senescence versus stemness is not simply antagonistic. The relationship depends on whether the setting is normal regeneration, aging tissue, reprogramming, or cancer. The paper’s Figures 2 and 3 are especially helpful because they map specific cell types, tissues and mechanisms into either antagonistic or synergistic categories.
A second novel aspect is the emphasis that senescence-associated stemness may be a transitional cancer state. The review brings together evidence that senescent cancer cells can harbour latent stemness traits before either remaining arrested, influencing neighbours through SASP, or escaping senescence with more aggressive properties.
A third useful point is the distinction between transient versus chronic SASP. Transient SASP may support repair and reprogramming, whereas chronic SASP tends to promote inflammation, impaired regeneration, and cancer stemness.
A fourth notable feature is the clinical framing: the authors connect the biology to senolytics, cancer therapy, regenerative medicine and patient stratification. They argue that senescence cannot simply be labelled “good” or “bad”; the therapeutic target depends on timing, tissue, burden, and whether the senescent cells are likely to be cleared.
Critique
The main weakness is that the paper is necessarily heterogeneous. It compares MSCs, muscle satellite cells, dental pulp stem cells, pancreatic β-cells, lymphomas, liver cancer, colon cancer, lung epithelial models and reprogramming systems. That breadth is useful, but it makes the central thesis partly dependent on analogies across very different biological systems.
A second limitation is that “senescence” is not always measured with the same rigor across the studies reviewed. The authors acknowledge this themselves in the conclusion, noting that some senescence detection methods, especially SA-β-Gal and SPiDER-βGal-based approaches, can have limitations. This matters because the argument depends heavily on whether the cells in question are truly senescent, transiently arrested, damaged, differentiating, stressed, or in some hybrid state.
A third issue is that the review could distinguish more sharply between cell-autonomous senescence–stemness coupling and paracrine SASP-mediated effects. These are mechanistically different. A senescent cell acquiring stemness markers is not the same as a senescent fibroblast inducing stemness in nearby cancer cells. The paper covers both, but the conceptual categories could be cleaner.
A fourth limitation is that the cancer section may overstate the generality of senescence-driven stemness. Therapy-induced senescence can indeed be dangerous if senescent cells persist or escape, but in many cancer contexts senescence remains a tumour-suppressive barrier. The paper recognises this, but the “dark side” framing could lead readers to underweight the value of stable senescence plus immune clearance.
A fifth point is that the review is light on metabolic and epigenetic integration. It mentions metabolic rewiring, mTOR, ROS, Wnt, p16/p21, SASP and reprogramming, but does not deeply integrate these with acetyl-CoA availability, chromatin acetylation, mitochondrial function, splicing, NAD biology, or mitochondrial membrane potential. Given the connection between senescence, stem-cell exhaustion and epigenetic state, this is a missed opportunity.
Finally, the therapeutic discussion is cautious but still underdeveloped. Senolytics are proposed as potentially useful, especially to prevent persistent therapy-induced senescence in cancer, but the review does not provide a robust framework for deciding when to use senolytics, senomorphics, mTOR inhibition, antioxidants, immune clearance enhancement, or pro-senescence therapy.
Bottom line
This is a useful and well-structured review. Its strongest contribution is showing that the senescence–stemness relationship is context-dependent: antagonistic in many aging/regenerative settings, but potentially synergistic and dangerous in cancer. Its main limitation is that it synthesizes many diverse systems under a broad conceptual umbrella, while the mechanistic and clinical distinctions between them remain only partly resolved.